NCT04586153View on ClinicalTrials.gov

Study to Assess the Effect of Meplazumab on COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

December 18, 2022

Conditions
COVID-19
Interventions
DRUG

Meplazumab for Injection

humanized antibody target CD147

DRUG

Sterile normal saline (0.9%)

Sterile normal saline (0.9%)

Trial Locations (1)

Unknown

Pesquisare Saúde, Santo André

All Listed Sponsors
lead

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

INDUSTRY

NCT04586153 - Study to Assess the Effect of Meplazumab on COVID-19 | Biotech Hunter | Biotech Hunter